Attention Investors: Note: The depositories (CDSL/NSDL), in coordination with SEBI, have upgraded their investor mobile applications to provide a consolidated view of investors’ holdings in securities markets. CDSL: MyEasiApp | NSDL: Speede App Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.
Experience finance made simple on the new ABCD app!
Scan to Download the App
One stop solution for all stock market enthusiasts
Whatsapp us!! We are Available.
Send HI on 8828800038
For Broking services
Call Toll Free Number :
1800-270-7000
( Mon - Fri: 9AM - 11PM )
( Sat & Sun: 9AM - 09PM )
Call N Trade
Call :
1800-108-9999
( 9AM to 11:30PM /11:55PM )
Acquire & service self-trading online & offline clients. Archive large-scale business success with the entire product range offered by us.
Earn while you refer client. No need to set up your own infrastructure.
Join our referral program, earn rewards when friends and family open accounts & transact. Spread the word, multiply your earnings!
Join the Entrepreneurial Tribe!
Aditya Birla Money Limited
Symbol : JBCHEPHARM | BSE Code : 506943 | Sector : PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN
Market Cap (₹ Cr.)
Turnover (₹ Cr.)
16/05/2026 BSE -0.65(-0.03)Close Price: ₹ 2,137.15 Volume: 1,646.00
16/05/2026 BSE 43.00(2.05)Close Price: ₹ 2,137.80 Volume: 158,319.00
16/05/2026 BSE -39.00(-1.83)Close Price: ₹ 2,094.80 Volume: 14,362.00
16/05/2026 BSE -74.05(-3.35)Close Price: ₹ 2,133.80 Volume: 17,150.00
16/05/2026 BSE 55.95(2.60)Close Price: ₹ 2,207.85 Volume: 16,715.00
No Data Available
J B Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 11 May 2026, inter alia, have recommended the final dividend of Rs 9.3 per equity Share (i.e. 930%) , subject to the approval of the shareholders.
Board of J B Chemicals & Pharmaceuticals recommends final dividend
J B Chemicals & Pharmaceuticals consolidated net profit declines 30.42% in the March 2026 quarter
J B Chemicals & Pharmaceuticals Ltd extends upmove
In Cr.
J B Chemicals & Pharmaceuticals Limited (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs). The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd. JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into a MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from April 2000.Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines.In Feb. 2002 the company has achieved another break through in its major R & D Activity - Invention biologically active molecules - New Chemical Entity. In 2001-02 the company introduced 3 products Reducin XX and two in the Cholesterol reducing segment i.e., Ifistatin and Vasolip. The company has launched five new products during the year 2003-04 in the global markets to widen its product portfolio. During 2004-05, the company launched new prod